Weight Loss — 2026-05-08
"Reta vs Ozempic" is one of the most-asked questions in metabolic peptide research, and for good reason — Ozempic is the brand that put GP-1 agonism on the map, and reta is the next-generation triple agonist that the field is now calibrating against it. This article walks through what each compound is, how they differ mechanistically, what the trial data actually shows, and where each one fits in a research protocol.
Quick note for researchers sourcing material: code WELCOME at checkout unlocks 35% off reta 10mg and 20mg vials, sema 10mg vials, and the Metabolic Stack — all batch-matched with full COAs.
Ozempic is the brand name for sema marketed for type 2 diabetes (typical labeled doses 0.5–2 mg weekly). The same molecule is sold under the brand Wegovy at higher doses (up to 2.4 mg weekly) for chronic weight management. Importantly, the active pharmaceutical ingredient is identical — the brand difference is dose, label, and indication.
Sema is a long-acting GP-1 receptor agonist with an albumin-binding fatty acid chain that gives it a half-life of approximately 7 days. Mechanistically, it produces:
That's it — one receptor, one axis, well-characterized.
Reta is a triple agonist at the GP-1, GIP, and glucagon receptors. The added mechanisms beyond what sema does:
The glucagon arm is the structurally novel piece. By activating glucagon (which raises energy expenditure) alongside GP-1/GIP (which suppress intake), reta hits both sides of the energy-balance equation simultaneously. Sema only hits the intake side.
The two compounds have not been studied in a single head-to-head trial as of this writing, but the published data is striking:
| Compound | Trial | Top-dose weight loss | Duration |
| Sema (Ozempic-equivalent dose, 1 mg) | SUSTAIN-6 / typical T2D programs | ~6% | 56-104 weeks |
| Sema (Wegovy-equivalent dose, 2.4 mg) | STEP 1 | ~14.9% | 68 weeks |
| Reta (12 mg) | Jastreboff et al. Phase 2 | ~24.2% | 48 weeks |
At the diabetes-labeled Ozempic dose (1–2 mg), weight loss is real but modest — typically 5–7% of baseline body weight in T2D populations. Reta's 12 mg arm produced roughly 3–4× the weight loss of an Ozempic-equivalent dose in less time.
Even reta's 4 mg arm (the lowest dose tested) produced ~17% weight loss — already exceeding what Ozempic-dose sema delivers.
This is where Ozempic earns its place in the research landscape. The diabetes program for sema is enormous:
Reta produces somewhat larger HbA1c reductions, but the *absolute difference* is smaller than the weight-loss gap. For a study where glycemic control is the primary endpoint and weight is secondary, sema's far longer track record of safety data (decades, millions of patient-years) is a significant consideration in research design.
Both compounds share the GP-1 class side-effect profile:
Reta adds glucagon-mediated effects on top:
In the Phase 2 obesity trial, GI adverse events were the most common reason for discontinuation in the higher-dose reta arms. By comparison, Ozempic-dose sema has lower discontinuation rates because the dose is lower and the receptor coverage is narrower.
| Reta | Sema (Ozempic-equiv.) | |
| Frequency | Weekly | Weekly |
| Half-life | ~6 days | ~7 days |
| Receptors | GP-1 + GIP + glucagon | GP-1 only |
| Trial weight loss | ~24% | ~6% (Ozempic dose) |
| Trial HbA1c | ~−2.2% | ~−1.7% |
| Titration steps | 5 (2 → 12 mg) | 3 (0.25 → 1 mg) |
| Approved | No (research only) | Yes (T2D) |
| Long-term safety data | Phase 2 only | Decades |
If you're running a head-to-head or sequential comparator study, batch-matched material is essential. Variable purity between vials is one of the most common confounders in early-phase peptide research. Both reta and sema are available individually and in the Metabolic Stack format from our catalog.
Code WELCOME at checkout unlocks 35% off Reta 10mg, Reta 20mg, Sema 10mg vials, and the Metabolic Stack. Every vial ships with a batch-matched COA showing 99%+ HPLC purity and US-based handling — the cleanest way to source matched material for a comparison protocol.
Disclaimer: All information presented in this article is for educational and informational purposes only. Platinum Biolabs does not promote or endorse the use of peptides for human consumption. All products sold by Platinum Biolabs are intended strictly for laboratory and research use only. Consult a qualified healthcare professional before making any health-related decisions.